- Pulmonx to Report First Quarter 2024 Financial Results on May 1, 2024
- Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer
- Pulmonx Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- Pulmonx Reports Fourth Quarter and Full Year 2023 Financial Results
- Pulmonx Announces Retirement of CEO Glen French and Appointment of Industry Veteran Steve Williamson as President and Chief Executive Officer
- Pulmonx to Report Fourth Quarter and Full Year 2023 Financial Results on February 21, 2024
- Pulmonx to Present at the Piper Sandler 35th Annual Healthcare Conference
- Pulmonx to Participate at Upcoming Investor Conferences
- Pulmonx Reports Record Third Quarter 2023 Financial Results
- Pulmonx to Report Third Quarter 2023 Financial Results on October 30, 2023
More ▼
Key statistics
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 7.43 |
---|---|
High | 7.51 |
Low | 7.21 |
Bid | 3.00 |
Offer | 7.61 |
Previous close | 7.50 |
Average volume | 601.60k |
---|---|
Shares outstanding | 38.81m |
Free float | 37.00m |
P/E (TTM) | -- |
Market cap | 291.09m USD |
EPS (TTM) | -1.60 USD |
Data delayed at least 15 minutes, as of Apr 18 2024 21:00 BST.
More ▼